Immunotherapy for the Treatment of Triple-Negative Breast Cancer

At JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®, presented on recent clinical trial data for approved immune checkpoint inhibitors and antibody-drug conjugates, and their implications in the current treatment landscape, for metastatic triple-negative breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolaney, Sara M., Shaw, Lindsay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126339/
https://www.ncbi.nlm.nih.gov/pubmed/35663156
http://dx.doi.org/10.6004/jadpro.2022.13.3.23
_version_ 1784712105293774848
author Tolaney, Sara M.
Shaw, Lindsay
author_facet Tolaney, Sara M.
Shaw, Lindsay
author_sort Tolaney, Sara M.
collection PubMed
description At JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®, presented on recent clinical trial data for approved immune checkpoint inhibitors and antibody-drug conjugates, and their implications in the current treatment landscape, for metastatic triple-negative breast cancer. Dr. Tolaney and Ms. Shaw also discussed principles of monitoring and managing adverse events associated with immunotherapies.
format Online
Article
Text
id pubmed-9126339
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-91263392022-06-04 Immunotherapy for the Treatment of Triple-Negative Breast Cancer Tolaney, Sara M. Shaw, Lindsay J Adv Pract Oncol Meeting Reports At JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®, presented on recent clinical trial data for approved immune checkpoint inhibitors and antibody-drug conjugates, and their implications in the current treatment landscape, for metastatic triple-negative breast cancer. Dr. Tolaney and Ms. Shaw also discussed principles of monitoring and managing adverse events associated with immunotherapies. Harborside Press LLC 2022-04 2022-05-23 /pmc/articles/PMC9126339/ /pubmed/35663156 http://dx.doi.org/10.6004/jadpro.2022.13.3.23 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Tolaney, Sara M.
Shaw, Lindsay
Immunotherapy for the Treatment of Triple-Negative Breast Cancer
title Immunotherapy for the Treatment of Triple-Negative Breast Cancer
title_full Immunotherapy for the Treatment of Triple-Negative Breast Cancer
title_fullStr Immunotherapy for the Treatment of Triple-Negative Breast Cancer
title_full_unstemmed Immunotherapy for the Treatment of Triple-Negative Breast Cancer
title_short Immunotherapy for the Treatment of Triple-Negative Breast Cancer
title_sort immunotherapy for the treatment of triple-negative breast cancer
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126339/
https://www.ncbi.nlm.nih.gov/pubmed/35663156
http://dx.doi.org/10.6004/jadpro.2022.13.3.23
work_keys_str_mv AT tolaneysaram immunotherapyforthetreatmentoftriplenegativebreastcancer
AT shawlindsay immunotherapyforthetreatmentoftriplenegativebreastcancer

Ejemplares similares